Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499323 | 0.85 | MCL1 (0.50) | KDM4EMCL1 | |
| SCHEMBL3499722 | 0.85 | HIF1A (0.55) | KDM4EALOX5HIF1ATARBP2MAOB | |
| SCHEMBL3498198 | 0.84 | KDM4E (0.43) | KDM4EMCL1ALDH1A1HSD17B10 | |
| SCHEMBL3498194 | 0.84 | MCL1 (0.40) | KDM4EALOX5MCL1ALDH1A1TSHR | |
| SCHEMBL3499188 | 0.84 | MAPT (0.41) | KDM4EALOX5MAPTALDH1A1 | |
| SCHEMBL3498599 | 0.83 | KDM4E (0.61) | KDM4EALOX5HIF1ATARBP2MAOB | |
| SCHEMBL5271564 | 0.82 | NPSR1 (0.40) | KDM4EALOX5HIF1AMAPTMCL1 | |
| SCHEMBL3498481 | 0.81 | PLK1 (0.54) | KDM4EPLK1ALOX5HIF1AMAPT | |
| SCHEMBL13344443 | 0.80 | TSHR (0.48) | MAPTALDH1A1TSHRLMNA | |
| SCHEMBL3500038 | 0.78 | PPID (0.38) | KDM4EMAPTALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | KDM4E 2059/4885PLK1 3152/4885ALOX5 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.